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The aim of this experiment was to establish whether verapamil, nicardipine, and nitroglycerin have (1) infarct size-limiting eﬀects
and (2) antiarrhythmic eﬀects in in vivo rabbit hearts during ischemia/reperfusion. Rabbits received regional ischemia by 30min
of left anterior descending coronary artery occlusion followed by 3 hours of reperfusion under ketamine and xylazine anesthesia.
The animals were randomly assigned to the following 4 treatment groups: a control group, a verapamil group, a nicardipine
group, and a nitroglycerin group. A continuous infusion of verapamil, nicardipine, or nitroglycerin was initiated 5min prior
to ischemia. Infarct size/area at risk decreased in verapamil, and nitroglycerin. The incidence of ischemia-induced arrhythmia
decreased in nicardipine, verapamil and nitroglycerin. The incidence of reperfusion-induced arrhythmias decreased in verapamil
andnitroglycerin.Fromthepresentexperimentalresults,verapamilandnitroglycerinratherthannicardipinedidaﬀordsigniﬁcant
protection to the heart subjected to ischemia and reperfusion in a rabbit model.
1.Introduction
Myocardial ischemia/reperfusion injury and its prevention
have become the focus of considerable attention. It was
reported that intracellular calcium overload is a recognized
common pathway that can explain ischemia/reperfusion
injury [1].
Several studies have shown that L-type calcium antag-
onists have beneﬁcial eﬀects on the ischemic myocardium
by inhibiting transmembrane calcium inﬂux in cardiac and
vascular smooth muscle [2, 3].
On the other hand, previous experimental studies have
investigated eﬀects of nitric oxide (NO) donors to reduce
myocardial ischemia/reperfusion injury [4, 5].
Thiscardioprotectionisduetothemechanismthatnitro-
glycerin is converted in vascular smooth muscle cells to NO
and relaxes vascular muscle of the large veins and coronary
arteries.Asaresult,nitroglycerincanreducepreloadandalso
provide an increased blood ﬂow to the heart.
It is clear that calcium antagonists and NO donors
have cardioprotective eﬀects. However, there is no study
examining the intensity of myocardial protection of these
drugs as indexes of infarct size and arrhythmias.
The aim of this experiment was to establish whether
verapamil, nicardipine, and nitroglycerin have infarct size-
limiting eﬀects and antiarrhythmic eﬀects in in vivo rabbit
hearts during ischemia/reperfusion.
2.MaterialsandMethods
The present study was performed in accordance with the
Guidelines of Animal Care and Use Committee of Kanagawa
Dental College.
2.1. General Surgical Preparation. Male New Zealand White
rabbits weighing 2.7–3.2kg were allowed ad libitum access to
standard laboratory stock diet and water. Animals were ini-
tially anesthetized with ketamine (35mg·kg−1) and xylazine
(5mg·kg−1) given intramuscularly. Five mL of 1% lidocaine
was subcutaneously injected as an additional local anesthetic
during the initial surgical procedures. Tracheotomy was
performed and rabbits were intubated with an uncuﬀed2 Anesthesiology Research and Practice
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Figure 1: Schematic diagram of the protocol. Group C: a control group (n = 9). Group NC: a nicardipine group (n = 5). Group V: a
verapamil group (n = 8). Group NT: a nitroglycerin group (n = 10).
endotracheal tube (ID 3.5mm). The animals were ventilated
with room air supplemented with additional oxygen using
mechanical ventilator (Shinano, SN-480-5, Tokyo, Japan)
and a semiclosed breathing circuit (Shinano, SN-487, Tokyo,
Japan). End-tidal CO2 partial pressures were continuously
monitored using a multigas monitor (Datex, Capnomac,
Helsinki, Finland). Ventilator rate was 30–35 breaths per
minute and tidal volume was between 30–35mL. The respi-
ratory rate was frequently adjusted to maintain PaO2 greater
than 100mmHg, PaCO2 at 35–45mmHg, pH 7.35–7.45, and
Base Excess between −3 and +3. After the left jugular vein
was exposed and cannulated with a polyethylene catheter,
0.9% sodium chloride (0.15mL·min−1) was continually
administered during the experiments. The carotid artery was
dissected out and ﬂuid-ﬁlled polyethylene tube was placed
in it and connected immediately to an electrocardiogram
monitor (Nihon-kohden Co, Life scope 11, Tokyo, Japan)
viapressure transducer (Nihon-kohden Co, TP-400T, Tokyo,
Japan) for arterial pressure recording. An electrocardiogram
was recorded throughout the experiment via lead II of
the standard electrocardiogram. Ischemia or reperfusion-
induced arrhythmias included premature ventricular con-
traction (PVC) and ventricular tachycardia (VT). After
all the surgical procedures had been performed, a 15-
minute period was allowed for stabilization. Anesthesia was
maintained with ketamine and xylazine solution (ketamine
35mg·kg−1·h−1, xylazine 5mg·kg −1·h−1 i.m.; K/X) with
room air supplemented with additional pure oxygen.
Left thoracotomy was performed and pericardium was
opened to expose the heart. A silk thread ( K-890H, Ethicon,
Somerville, NJ ) with taper C-1 needle was passed around
the left anterior descending artery (LAD) and the end of
the tie was threaded through a small vinyl tube to form a
snare. The LAD was occluded by pulling the snare, which
was then ﬁxed by clamping the tube with a mosquito
hemostat. The rabbits were given 500 units of heparin
for preventing thrombus formation in the coronary artery
after reperfusion. Myocardial ischemia was conﬁrmed by
regionalcyanosis,STsegmentelevation,anddecreasedblood
pressure. Reperfusion was conﬁrmed by reactive hyperemia
over the surface after releasing the snare.
2.2. Study Groups and Experimental Protocol. The experi-
mental design used in the current study is illustrated in
Figure 1. Rabbits received regional ischemia by 30min of
the LAD occlusion followed by 3hrs of reperfusion under
ketamine/xylazine (K/X) anesthesia. Before this, rabbits were
randomly assigned to the following 4 treatment groups
(n = 5 ∼ 9, resp.): a control group (Group C), verapamil
(Group V), nicardipine (Group NC), and nitroglycerin
(Group NT) treatment group. A continuous infusion of ver-
apamil (0.1mg·kg−1·h−1), nicardipine (0.06mg·kg−1·h−1),
or nitroglycerin (0.06mg·kg−1·h−1) was initiated 5min
prior to ischemia. Therapeutic dose of each drug was
administered.
2.2.1. Determination of Area at Risk and Infarct Size. Fol-
lowing completion of experimental protocol, the in vivo
visualization of the myocardium at risk was accomplished
with reocclusion of the coronary artery and injection of
10% Evans blue into the venous cannula until the eyes
turned blue. The Evans blue was allowed to circulate for
about 30sec to demarcate the risk and nonrisk regions. The
hearts were quickly excised under deep anesthesia with 5%
sevoﬂurane and frozen. The frozen hearts were then cut
into six transverse slices of equal thickness. The area at risk
was determined by negative staining with Evans blue. The
slices were stained by incubation for 15min in 1% triphenyl
tetrazolium chloride (TTC) in isotonic pH 7.4 phosphateAnesthesiology Research and Practice 3
buﬀer. After staining, the sections were placed in formalin
for preservation, and measurements of risk area, infarct
area, and left ventricle were made with computer-aided
morphometry. From each section, the ischemic risk area
(unstained by blue dye) and the infarcted area (unstained by
TTC) were outlined and measured by planimetry. The area
from each region was averaged from the slices. Infarct size
was expressed as a percentage of the area at risk.
2.3. Hemodynamic Measurements. Hemodynamic measure-
ments included systolic, diastolic, mean arterial blood pres-
sures, and heart rate. Rate pressure product was calculated
as the product of heart rate and peak arterial pressure.
Baseline hemodynamic measurements were taken prior to
anyexperimentalmanipulations.Subsequently,themeasure-
ments were taken at preischemia, 30 min of ischemia, and 30
and 60min of reperfusion.
2.4. Limitation Section. Rabbits which could not be survived
until the end of experiments with lethal arrhythmias such
as ventricular ﬁbrillation (VF) have been excluded from the
data analysis and not considered further.
2.5. Statistical Analysis. Between-group diﬀerences in area at
risk/left ventricle, infarct size/area at risk, and duration of
arrhythmias were assessed by Kruskal-Wallis test followed by
Dunn’s procedure as a multiple comparison procedure.
Statistical comparisons of individual hemodynamic
parameters between groups were made by using one-way
analysis of variance (ANOVA) followed by Fisher’s protected
least signiﬁcant diﬀerence. Bartlett’s test for equality of
variances was used to ensure the validity of statistical
comparison using the one-way ANOVA.
Thediﬀerenceinthepercentageincidenceofarrhythmias
was analyzed with a χ2 test.
All data are reported as group mean±SD and were
considered statistically signiﬁcant at a probability value (P)
less than .05.
3. Results
Hemodynamics during ischemia and reperfusion are shown
in Table 1. Heart rate (HR) was signiﬁcantly reduced in
Group NT 30min after reperfusion. Mean arterial blood
pressure (MAP) was signiﬁcantly reduced in Group V and
Group NT at any point measured and in Group NC 60min
after reperfusion and preischemia. Rate pressure product
(RPP) did not alter signiﬁcantly among Group C, Group
NC, and Group V. However, there was signiﬁcant diﬀerence
between Group C and Group NT 30min after ischemia, and
30 and 60 min after reperfusion.
The ratio of areas at risk (R) to left ventricle (L)r a n g e d
from51.9±8.7%to64.8±5.3%withnosigniﬁcantdiﬀerence
among all the groups (Figure 2). Figure 3 shows the infarct
size expressed as percentage of area at risk in four groups.
Mean infarct size was 62.1 ± 3.1% of R in Group C and
decreased signiﬁcantly in Group V (51.3 ±3.1%) and Group
NT (45.1 ± 3.6%) (P<. 05 versus Control) (Figure 3).
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Figure 2: The ﬁgure shows R/L value (%), which means the area at
risk expressed as percentage of left ventricle. Data are expressed as
mean±S.D. Area at risk revealed no signiﬁcant diﬀerence among
all groups, suggesting that the changes in the infarct size observed
among the groups did not depend on R/L. Group C: a control
group.GroupNC:anicardipinegroup.GroupV:averapamilgroup.
Group NT: a nitroglycerin group.
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Figure 3: The ﬁgure shows I/R value (%), which means the infarct
size expressed as percentage of area at risk. Group C: a control
group.GroupNC:anicardipinegroup.GroupV:averapamilgroup.
Group NT: a nitroglycerin group. # Signiﬁcantly diﬀerent (P<. 05)
from Group C (mean±S.D.).
C o m p a r e dw i t hG r o u pC ,m y o c a r d i a lp r o t e c t i v ee ﬀect was
observed in the Group V and Group NT.
The incidence of arrhythmias during myocardial
ischemia was 33.3% in Group C, 0% in Group NC and
Group V, and 14.3% in Group NT (Figure 4). The incidence
ofarrhythmiasduringreperfusionwas88.9%,80.0%,60.0%,
and 50.0% in Group C, Group NC, Group V, and Group4 Anesthesiology Research and Practice
Table 1: Hemodynamics during ischemia and reperfusion.
Group Preischemia 30min after ischemia 30min after reperfusion 60min after reperfusion
HR (beats/min)
Group C 158.1±18.9 171.7±12.8 163.9±14.9 159.9±14.7
Group NC 168.0±25.7 153.0±10.8 154.6±18.9 164.8±32.5
Group V 167.3±22.6 176.4±27.1 169.3±19.3 162.0±24.8
Group NT 155.1±19.0 156.9±20.2 146.3±19.9∗ 147.6±12.1
MAP (mmHg)
Group C 70.0±5.1 63.0±8.0 63.8±7.9 64.3±8.8
Group NC 49.8±13.0# 55.8±8.5 58.4±8.7 51.5±11.5#
Group V 56.8±7.2# 52.4±5.5# 51.4±4.4# 51.3±4.6#
Group NT 52.5±5.5# 52.8±3.6# 52.7±4.2# 52.5±2.1#
RPP (mmHg/min)
Group C 13167.2±562.0 12765.5±606.6 12478.4±552.1 12438.1±563.2
Group NC 11201.8±1459.6 11316.8±1233.0 11387.4±1219.1 11318.6±1418.4
Group V 11421.3±417.0 11270.3±548.1 10918.9±430.1 10485.0±469.0
Group NT 10799.0±348.7 10584.2±239.2# 10002.5±445.0# 9863.7±362.0#
H R :h e a r tr a t e .M A P :m e a na r t e r i a lb l o o dp r e s s u r e .R P P :r a t ep r e s s u r ep r o d u c t .#Signiﬁcantly diﬀerent (P<. 05) from Group C (mean±S.D.). ∗Signiﬁcantly
diﬀerent (P<. 05) from Group V (mean±S.D.).
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Figure 4: The ﬁgure shows incidence of arrhythmias during
myocardial ischemia. Group C: a control group. Group NC: a
nicardipine group. Group V: a verapamil group. Group NT: a
nitroglycerin group. # Signiﬁcantly diﬀerent (P<. 05) from Group
C (mean±S.D.).
NT, respectively (Figure 5). Duration of arrhythmias during
myocardial ischemia were 48.4sec, 0sec, 0sec, and 0.2sec in
Group C, Group NC, Group V, and Group NT, respectively
(Figure 6). Duration of arrhythmias during reperfusion were
453.7sec, 63.8sec, 97.1sec, and 73.0sec in Group C, Group
NC, Group V, and Group NT, respectively (Figure 7).
4. Discussion
The present study shows that verapamil and nitroglycerin
rather than nicardipine did aﬀord signiﬁcant protection to
the heart subjected to ischemia and reperfusion in a rabbit
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Figure 5: The ﬁgure shows incidence of arrhythmias during reper-
fusion. Group C: a control group. Group NC: a nicardipine group.
Group V: a verapamil group. Group NT: a nitroglycerin group.
# Signiﬁcantly diﬀerent (P<. 05) from Group C (mean±S.D.).
model as indexes of myocardial infarct size and duration of
ventricular arrhythmias during ischemia and reperfusion.
Protocol to prevent necrosis by calcium-blocker may
vary greatly among researchers with regard to the choice of
drugs, dose, time of administration, collateral blood ﬂow of
the animals, and diﬀerence of experiment system [2, 6]. In
this experiment, we used rabbit hearts of which coronary
collateral blood ﬂow is almost zero like human hearts [7, 8].
Reimer and Jennings reported that verapamil reduced
infarct size induced by 40min of ischemia in in vivo dog,
but failed to limit infarct size when the period of ischemia
was prolonged to 3 hours. However, pretreatment with
verapamil 15min before ischemia prevented necrosis ofAnesthesiology Research and Practice 5
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Figure 6: The ﬁgure shows duration of arrhythmias during
myocardial ischemia. Group C: a control group. Group NC: a
nicardipine group. Group V: a verapamil group. Group NT: a
nitroglycerin group. # Signiﬁcantly diﬀerent (P<. 05) from Group
C (mean±S.D.).
myocytes, though the treatment started 15min after the
onset of ischemia failed to limit infarct size [2]. The ability
of verapamil to reduce infarct size seems to be aﬀected by the
duration of ischemia and time of initiation of therapy. In this
study, pretreatment with verapamil 5min before ischemia
reduced infarct size induced by 30min of ischemia. It seems
that pretreatment with verapamil before ischemia may be
required to reduce infarct size in rabbit hearts.
L-type calcium antagonists such as verapamil have
positive eﬀects on contractile function of ischemic myocytes
during ischemia and have improved postischemic recovery
of function [9]. The rational for using verapamil to reduce
myocardial infarct size includes their ability to (1) reduce
oxygen demand by reducing afterload, preload and con-
tractility; (2) enhance oxygen supply to the ischemic zone
by relieving coronary vasospasm and vasocontraction, (3)
prevent ischemia-induced calcium overload; (4) preserve
mitochondrial structure and function [9, 10], (5) decrease
the availability of calcium to stimulate ATPase, proteases
and lipases [6]. Our study showed that the rate pressure
product, which is one index of myocardial oxygen demand,
didnotsigniﬁcantlydiﬀerbetweenthecontrolandverapamil
groups. This suggests that the infarct size-limiting eﬀect by
verapamil does not depend on myocardial oxygen demand
and supply.
On the contrary, nicardipine failed to decrease infarct
size. Nicardipine is a dihydropyridine derivative and a
potent coronary and cerebral vasodilator [3]. Although in
baboons and dogs, infarct size-limiting eﬀects of nicardipine
have been previously reported [3, 11], nicardipine had no
appreciable activity in our rabbit model. It is probably
due to the diﬀerences of receptivity of nicardipine, species,
administration, length of ischemia, and extent of collateral
blood ﬂow [7, 8]. Verapamil mainly aﬀects the myocardium,
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Figure 7: The ﬁgure shows duration of arrhythmias during reper-
fusion. Group C: a control group. Group NC: a nicardipine group.
Group V: a verapamil group. Group NT: a nitroglycerin group.
# Signiﬁcantly diﬀerent (P<. 05) from Group C (mean±S.D.)
whereas nicardipine exerts a greater eﬀect on smooth muscle
in the peripheral vasculature. It may cause reﬂex tachycardia
if peripheral vasodilatation is marked, resulting in a sub-
stantial decrease in blood pressure [12]. It is assumed that
nicardipine-induced tachycardia, unlike verapamil, might
increase myocardial oxygen consumption and reduce the
infarct size-limiting eﬀect [13]. However, it does not seem to
be this mechanism because nicardipine did not signiﬁcantly
aﬀect HR and RPP in this study.
Nitroglycerin has been used to treat angina and heart
failure. It is assumed that nitroglycerin is converted in
vascular smooth muscle cells to NO or an NO congener
(S-nitrosothiol, SNO), which activates guanylate cyclase and
thus relaxes vascular smooth muscle [14]. Their vasodilator
activity decreases myocardial oxygen demand by reducing
venous return to the heart. NO, therefore, plays a cru-
cial role in cardioprotection [15]. At therapeutic doses,
nitroglycerin has two major eﬀects. First, it causes dilation
of the large veins, resulting in pooling of blood in the
veins. This diminishes preload and reduces the work of the
heart. Second, nitroglycerin dilates the coronary vasculature,
providing an increased blood supply to the heart muscle.
Nitroglycerin decreases myocardial oxygen consumption
because of decreased cardiac work [12]. Our experimental
data also demonstrated that nitroglycerin reduced RPP.
Therefore, smaller myocardial infarct size may be explained
by smaller oxygen consumption.
Nitroglycerin has been shown, in both human and
animal studies, to induce a prospective phenotype that
limits tissue damage after ischemia and reperfusion. This
phenomenon is similar to ischemic preconditioning, and
several reports suggest that the molecular pathways involved
in this protective eﬀect of nitrates are the same that
determine ischemic preconditioning [16].6 Anesthesiology Research and Practice
A previous investigation from our laboratory demon-
strated that pretreatment with nitroglycerin 30min before
ischemia failed to limit infarct size [17]. However, the
same dose of nitroglycerin reduced infarct size when it was
administered 5min before ischemia. This indicates that the
ability of nitroglycerin to reduce infarct size depends on the
timing of its administration.
Myocardial ischemia/reperfusion injury might signiﬁ-
cantly impair heart functions and induce arrhythmias via
cellular Ca2+ overload [18]. Generally, the main cause of
ischemia-induced arrhythmias is aberrations in impulse
generation or a defect in impulse conduction [12]w h i c h
is prevented from calcium-blocker. On the other hand, the
main cause of reperfusion-induced arrhythmias remains
poorly studied. A delay after depolarization-induced activity
and an increase in Ca2+ concentration are thought to play
a role. Blocking the L-type Ca2+ channel has been shown
to be eﬀective in preventing reperfusion arrhythmias in
rats [18, 19]. In this study, verapamil, nicardipine, and
nitroglycerin have antiarrhythmic eﬀects during myocardial
ischemia. It was suggested that verapamil and nicardipine
could reduce arrhythmias by decreasing inﬂux of L-type
calciumcurrent.Onlynicardipinedidnotdecreaseincidence
of arrhythmias during reperfusion. Nicardipine, used to
treat hypertension, exerts a stronger eﬀect on the vascular
muscle than on the heart [12]. Therefore, it is not clinically
used as antiarrhythmic drug. As for nitroglycerin, there is a
reportthatNO,whichisconvertedfromnitroglycerin,blocks
L-type calcium channels [20]. There is a possibility that
nitroglycerin reduced incidence and duration of ventricular
arrhythmia by blocking calcium channel.
5. Conclusions
In this investigation, verapamil and nitroglycerin decreased
myocardial infarct size and incidence and duration of
ventricular arrhythmias during ischemia and reperfusion.
According to the present experimental results, verapamil and
nitroglycerin rather than nicardipine did aﬀord signiﬁcant
protectiontotheheartsubjectedtoischemiaandreperfusion
in a rabbit model.
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